… The success of tyrosine kinase inhibitors (TKIs) in select patients with non–small-cell lung
cancer (NSCLC) has transformed management of the disease, placing new emphasis on …

… the treatment of non–small cell lung cancer (NSCLC). The use of … development of EGFR
tyrosine kinase inhibitors, the discovery … of EGFR tyrosine kinase inhibitors (TKIs) in lung cancer. …

… Thus, kinases still remain the most effective molecular target in lung cancer therapy. Also,
once-shunned kinase inhibitors have recently acquired renewed interest after the …

… cell lung cancers express the Kit receptor tyrosine kinase … , suggesting that inhibitors of Kit
tyrosine kinase activity could … was designed as an Abl tyrosine kinase inhibitor, but also has …

… the kinase inhibitors. However, many gaps remain in understanding the mechanisms of kinase
inhibitors … and non-receptor tyrosine kinase inhibitors and their novel role in lung cancer. …

… kinase inhibitors gefitinib and erlotinib are effective therapies for non–small cell lung cancer
… these cancers. Studies over the last few years have identified two different EGFR tyrosine …

… with non–small cell lung cancer. Tyrosine kinase inhibitors have provided an illustrative
example of the successes in targeting oncogene addiction in cancer and the role of tumor-…

… Although the PI3K is undoubtedly important in lung cancers, no specific mutations in … lung
tumors to date (61). We would anticipate further development of PI3K inhibitors in lung cancer …

… therapeutic approach specifically in non–small-cell lung cancer (NSCLC). Given space
constraints, as … We also have limited discussion of kinase inhibitors to gefitinib (ZD1839, Iressa; …

… )–mutant lung cancer is a well-described molecular subgroup of lung adenocarcinoma …
EGFR–tyrosine kinase inhibitor (TKI; refs. 1, 2). Patients with EGFR-mutant lung cancer develop …